CTOs on the Move

Pharvaris

www.pharvaris.com

 
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pharvaris.com
  • 1 Cranberry Hill Suite 300
    Lexington, MA USA 02421
  • Phone: 212.845.4262

Executives

Name Title Contact Details
Stefan Abele
Chief Technical Operations Officer Profile

Similar Companies

Americare Medical Supply

At Americare Medical Supply, we are committed to the excellence in terms of our Quality Products, Standards of Service, and Pricing. Client satisfaction is our number one priority and we take pride in providing quality products that make a difference i...

Pafford Medical Services

With one call, Pafford Medical Services facilitates every component of patient transport on both sides of the horizon.

Althera

Althera Pharmaceuticals, a company focused on heart health, announces FDA approval of Roszet (rosuvastatin and ezetimibe) tablets. Founded in 2010, Althera develops innovative patient focused medicines to improve cardiovascular health.

Pliant Therapeutics

Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant`s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.